HK Stock Market Move | GigaDevice Semiconductor Inc. (03986) rises over 5%, Goldman Sachs significantly raises first-quarter DRAM price hike forecast.
Megvii Technology (03986) rose more than 5%, as of press time, up 5.59% to HK$321, with a turnover of HK$298.414 million.
GigaDevice Semiconductor Inc. (03986) rose more than 5%, as of the time of writing, it increased by 5.59%, to 321 Hong Kong dollars, with a turnover of 29.8414 million Hong Kong dollars.
On the news front, on Monday, South Korean memory giant stock prices fell sharply due to expectations of tightening overseas liquidity and the first drop in DRAM spot prices in months. However, in its latest report, Goldman Sachs pointed out that despite the fluctuations in the spot market, contract prices for DRAM not only did not fall, but also saw more aggressive expectations of an increase. Goldman Sachs analyst Giuni Lee's team noted that pricing forecasts for major application areas of DRAM in the first quarter of 2026 have been significantly revised upwards. In particular, the overall pricing of traditional DRAM is expected to achieve a further 90%-95% quarter-on-quarter increase in the first quarter of 2026, far exceeding market expectations and the bank's own previous expectations.
Related Articles
.png)
HK Stock Market Move | SF INTRA-CITY(09699) rose more than 4%, with an expected year-on-year profit growth of no less than 80% by 2025.

HK Stock Market Move | HENLIUS (02696) rose nearly 5% in early trading. The HLX22 head-to-head K drug for gastric cancer phase III clinical trial conducted by American researchers will be successfully held.

HK Stock Market Move | STANCHART (02888) rose more than 4% during trading, Standard Chartered's high-end individual client base in the Greater Bay Area saw strong growth in new clients. In the future, the company will increase market expansion in China.
HK Stock Market Move | SF INTRA-CITY(09699) rose more than 4%, with an expected year-on-year profit growth of no less than 80% by 2025.
.png)
HK Stock Market Move | HENLIUS (02696) rose nearly 5% in early trading. The HLX22 head-to-head K drug for gastric cancer phase III clinical trial conducted by American researchers will be successfully held.

HK Stock Market Move | STANCHART (02888) rose more than 4% during trading, Standard Chartered's high-end individual client base in the Greater Bay Area saw strong growth in new clients. In the future, the company will increase market expansion in China.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


